Circulating long noncoding RNA growth arrest‐specific transcript 5 as a diagnostic marker and indicator of degree of severity in plaque psoriasis

Abstract

Background The current study aims at evaluating the role of circulating or cell‐free long noncoding ribonucleic acid (lncRNA) growth arrest‐specific 5 (GAS5) in plaque psoriasis and at investigating its relationship with the presented clinical data. Methods This case‐control study was conducted on 180 subjects, divided into two main categories as follows: 90 cases with plaque psoriasis and 90 age‐ and sex‐matched healthy controls. Full history taking, thorough general examination, and full dermatological examination with determination of number and site of lesions were performed. Disease severity was assessed by Psoriasis Area Severity Index (PASI) score. Relative quantification of the expression level of cell‐free lncRNA (GAS5) was performed using real‐time polymerase chain reaction (RT‐PCR) technique. Results There was significant increase of GAS5 expression level in cases when compared with controls (U = 719.0, P < 0.001). Indeed, there was significant positive correlation between GAS5 and PASI score (r = 0.0.668, P < 0.001). Receiver operating characteristic (ROC) curve showed that GAS5 could identify patients from controls: GAS5 at a cut‐off value ≥0.31 provides a sensitivity of 95.56% and a specificity of 82.22%; at a cut‐off value ≥0.75, it can differentiate between mild and moderate cases, at a sensitivity of 77.78% and a specificity of 91.43%; at a cut‐off value ≥1.61, it can discriminate between moderate and severe cases, with a sensitivity of 71.43% and a specificity of 74.07%. Conclusion lncRNA GAS5 expression could be considered as a diagnostic marker of plaque psoriasis and indicator of its severity.

ILF2 Contributes to Hyperproliferation of Keratinocytes and Skin Inflammation in a KLHDC7B-DT-Dependent Manner in Psoriasis

“…LncRNAs have been revealed to participate in the pathogenesis of psoriasis, including MEG3, GAS5, and MIR31HG ( Gao et al, 2018 ; Jia et al, 2019 ; Ahmed Shehata et al, 2021 ). Here, we demonstrated that KLHDC7B-DT positively regulates the proliferation of keratinocytes.…”

Genetic and Epigenetic Mechanisms of Psoriasis

“…lncRNA-RP6- 65G23.1 is a significant upregulated lncRNA in psoriasis that promotes keratinocyte proliferation and suppression of apoptosis by modifying the expression of Bcl-xl, Bcl2 and the ERK1/2-AKT signaling pathway [ 86 ]. Other upregulated lncRNA in psoriasis are MIR31HG [ 87 ], MSX2P1 [ 88 ], XIST [ 89 ], FABP5P3 [ 90 ], KLDHC7B-DT [ 91 ], or SPRR2C [ 92 ]; whereas, MEG3 [ 93 ], GAS5 [ 94 ], PRINS [ 95 ] or NEAT1 [ 96 ] are downregulated in psoriasis.…”

Insights into the defensive roles of lncRNAs during Mycoplasma pneumoniae infection

“…As shown in the schematic in Figure 1, there are eight conventional lncRNAs regulatory mechanisms: (1) transcription interference involving transcription from the upstream promoter region of a target protein-coding gene (Figure 1A); (2) inhibiting RNA polymerase II or inducing chromatin remodeling or histone modification, which interferes with target gene transcription (Figure 1B); (3) generating complementary double strands involving mRNAs, which interferes with mRNA cleavage (Figure 1C); (4) generating endogenous short interfering RNAs (endo-siRNAs), which target specific mRNAs (RNA interference) (Figure 1D); (5) binding to a specific protein to modulate its activity (Figure 1E); (6) forming a ribozyme-protein complex, which catalyzes specific reactions (Figure 1F); (7) binding to a specific protein to alter its cellular localization (Figure 1G); and (8) producing small RNA precursors (Figure 1H). Some upregulated lncRNAs play a tumor-promoting role, while downregulated lncRNAs in gastric cancer play a tumor-inhibitory role (Figure 1B) (Ahmed Shehata et al, 2021). Some lncRNAs can regulate protein activity (Figure 1C).…”